Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ORNAV.HE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ORNAV.HE and 80,000+ other tickers.
See exactly how ORNAV.HE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ORNAV.HE and 80,000+ other tickers.
Orion Oyj is a globally operating pharmaceutical enterprise engaged in the research, development, manufacturing, and marketing of medicines for both human and animal health, alongside active pharmaceutical ingredients (APIs). Its commercial footprint spans Finland, Scandinavia, other European countries, North America, and numerous international markets. The company's human health portfolio encompasses a variety of prescription drugs and self-care products. Prominent prescription therapies include Nubeqa for prostate cancer; Dexdor and Precedex, utilized as intensive care sedatives; Stalevo…
No recent news available.